Streetbeat News

Analyst Ratings

JEF

Oppenheimer analyst Chris Kotowski has maintained an 'Outperform' rating on Jefferies Financial Group (NYSE:JEF) and raised the price target from $64 to $66.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:13 pm

SMR

CLSA has initiated coverage on NuScale Power (NYSE:SMR) with an Outperform rating and set a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:13 pm

CAL

Loop Capital has maintained a Hold rating on Caleres (NYSE:CAL) but has lowered the price target from $45 to $30, indicating a more cautious outlook on the stock.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:10 pm

NATR

Canaccord Genuity has initiated coverage on Natures Sunshine Products with a Buy rating and set a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:08 pm

UPBD

Loop Capital has maintained a Hold rating on Upbound Group (NASDAQ:UPBD) with a price target of $36, as per analyst Anthony Chukumba.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:08 pm

MNTX

Northland Capital Markets has downgraded Manitex International from Outperform to Market Perform and reduced its price target from $8 to $5.8.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 12:02 pm

SATS

EchoStar (NASDAQ:SATS) has received mixed analyst ratings, with a recent positive shift in average price targets. Analysts have raised and lowered their ratings, reflecting varied expectations. EchoStar faces financial challenges, including declining revenue and low profitability metrics, but maintains a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 12:01 pm

KIDS

OrthoPediatrics (NASDAQ:KIDS) has received mixed analyst ratings over the past three months, with two bullish and two indifferent ratings. The average 12-month price target has decreased by 5.1% to $37.25. Analysts have maintained or lowered their ratings, reflecting evolving market conditions. The company has shown strong revenue growth but faces challenges with asset utilization.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 12:01 pm

HALO

Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 12 analysts, with most ratings being bullish. The average 12-month price target is $61.67, reflecting a 3.51% increase from the previous target. Analysts have maintained or raised their ratings, indicating positive sentiment. Financially, Halozyme shows strong profitability and asset utilization but faces challenges with high debt levels.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 12:01 pm

TENB

Tenable Holdings (NASDAQ:TENB) received mixed analyst ratings, with a decrease in average price target from $56.31 to $50.57. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Despite revenue growth, Tenable faces challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 12:00 pm